P&S Market Research - A market research firm

Autologous Stem Cell and Non Stem Cell Based Therapy Market

Global Autologous Stem Cell and Non-Stem Cell Based Therapy Market Size, Share, Development, Growth and Demand Forecast to 2023

Delivery : 24-72 Working Hours
Report Code: LS10375
Available Format:
Category : Biotechnology

The global autologous stem cell and non-stem cell based therapy market is growing significantly due to high incidences of cancer and cardiovascular diseases, and presence of large number of patients requiring transplantation. The lack of service providers in the autologous stem cell market, and the massive unexplored autologous stem cell and non-stem cell based therapy market in the emerging economies, are creating ample growth opportunities for the global autologous stem cell and non-stem cell based therapy market. The advanced research and development activities and new product developments by the major players are supporting the demand for cost effective and efficient autologous stem cell and non-stem cell based therapy platforms.

The usage of multipotent stromal cell (mesenchymal stem cell) transplantation in multiple sclerosis is a trend, in the global autologous stem cell and non-stem cell based therapy market. In autologous stem cell and non-stem cell based therapy, an individual’s stem or non-stem cells are cultured outside the body and then transferred back into the body. The autologous cellular therapies do not require separate donor, instead it utilizes stem or non-stem cells from the individual who needs treatment for a particular disease. The U.S. Food and Drug Administration (FDA) defined the autologous use as “the implantation, transplantation, infusion, or transfer of human cells or tissue back into the individual, from whom the cells or tissue were recovered”. These cells are recovered mostly from the bone marrow or blood of the individual. Autologous cell therapy has better clinical results, and reduced rejection rate. The conventional treatment procedures with synthetic or allogenic materials have several disadvantages, such as abscess formation, foreign body granuloma formulation, and allergic reactions; however, the autologous stem cell and non-stem cell based therapy has overcome these limitations with better results.

The autologous stem cell and non-stem cell based therapy market is categorized as autoimmune diseases, cancer, neurodegenerative diseases, infectious diseases, and others.

Some of the factors driving the growth of the global autologous stem cell and non-stem cell based therapy market are technological advancements, reduction in risk associated with autologous stem cell and non-stem cell based therapy, growing number of chronic diseases, and increasing researchers’ and scientists’ compliance for autologous cellular therapies. In addition, the increasing government involvement and ease in regulation for autologous cellular therapies, increasing demand for cellular transplantation, and growing research and development activities in the autologous stem cell and non-stem cell based therapies is driving  the growth of the market. However, the high cost of autologous cellular therapies, side effects associated with it, and lack of skilled professionals are some of the factors restraining the growth of the global autologous stem cell and non-stem cell based therapy market to some extent.

Geographically, North America leads the global autologous stem cell and non-stem cell based therapy market, due to technological advancements, increased research and development activities, very few risk associated with autologous cellular therapies, high healthcare expenditure, and high incidences of chronic diseases. Asia-Pacific is the fastest growing region in the global autologous stem cell and non-stem cell based therapy market. The major reasons for the fastest growth in the region are increasing healthcare expenditure, increasing autologous stem cell and non-stem cell based therapy related research activities, improving healthcare infrastructure. Moreover, the autologous stem cell and non-stem cell based therapy market is growing rapidly, due its capability of treating a range of diseases such as autoimmune, cancer, and cardiovascular, in the emerging economies such as India and China.

Some of the major players operating in the global autologous stem cell and non-stem cell based therapy market are Fibrocell Science Inc., BrainStorm Cell Therapeutics Inc., Vericel Corporation, Dendreon Corporation, Lion Biotechnologies, Genzyme Corporation, Regeneus Ltd., Caladrius, and Opexa Therapeutics Inc.

 

Report Coverage

  • Provides comprehensive understanding of the market with the help of informed market outlook, opportunities, challenges, trends, size and growth, competitive analysis, major competitors and Porter analysis
  • Identifies the key drivers of growth and challenges of the key industry players. Also, assesses the future impact of the propellants and restraints on the market
  • Uncovers potential demands in the market
  • Porter analysis identifies competitive forces within the market
  • Provides information on the historical and current market size and the future potential of the market
  • Provides sizes of key regional markets using yardsticks of segments
  • Highlights the competitive scenario of the market and major competitors
  • Provides profiles of major competitors of the market including details of their operations, product and services, recent developments and key financial metrics. Profiles provide better understanding of competition as well as the demands of the market.

Place An Order

Single User License
question-mark

The report will be delivered in PDF format without printing rights. It is recommended for a single user.

USD 5100
Group License
question-mark

The report will be delivered in PDF format along with the printing rights. It is recommended for up to five users.

USD 6100
Enterprise License
question-mark

The report will be delivered in PDF format along with printing rights and detailed Excel sheet. It is recommended for organizations where multiple people would like to access the report from multiple locations.

USD 9100

Pre-Purchase Enquiry